SCHEMBL9104878

SCHEMBL9104878

CC(=O)Nc1cc(-c2nc(-c3ccccc3Cl)c(-c3ccccn3)o2)c(C)cn1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 4/20 0.41
TYK2 P29597 4/20 0.41
PIK3C3 Q8NEB9 2/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 2/20 0.39
ABL1 P00519 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
NUDT1 P36639 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9110703 0.86 PIK3C3 (0.39) PIK3C3HPGDTDP1ABL1SMN1; SMN2
SCHEMBL9889779 0.86 SMN1; SMN2 (0.40) JAK1TYK2PIK3C3ALDH1A1KDM4E
SCHEMBL16167587 0.85 PIK3C3 (0.40) JAK1TYK2PIK3C3TDP1ABL1
SCHEMBL627198 0.83 PIK3C3 (0.39) JAK1TYK2PIK3C3ALDH1A1TDP1
SCHEMBL9888652 0.83 PIK3C3 (0.39) PIK3C3HPGDTDP1ABL1SMN1; SMN2
SCHEMBL626945 0.83 PIK3C3 (0.45) PIK3C3ALDH1A1KDM4ETDP1ABL1
SCHEMBL9107251 0.83 PIK3C3 (0.40) JAK1TYK2PIK3C3ALDH1A1KDM4E
SCHEMBL626067 0.82 PIK3C3 (0.42) PIK3C3ALDH1A1KDM4ETDP1ABL1
SCHEMBL627354 0.82 PIK3C3 (0.43) JAK1TYK2PIK3C3ALDH1A1KDM4E
SCHEMBL626950 0.81 PIK3C3 (0.39) PIK3C3TDP1ABL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
WO-2012021615-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142732-A1 HETEROARYLS AND USES THEREOF PIK3R4, PIK3C2B, PIK3R1 JAK1 227/4885TYK2 2225/4885PIK3C3 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.